Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Tumor hyperinsulinism
Economic burden and healthcare resource utilization
7 evidence topics · 7 sources
Company description of hospitalization and deferred tumor treatment in tumor hyperinsulinism
Hospitalization and continuous parenteral dextrose among expanded access patients (company filing)
Inpatient days and parenteral glucose support in refractory malignant insulin-secreting tumors
“Six of the 8 individuals were hospitalized at EAP entry (median, 28 days; range, 4-66 days), largely due to glycemic instability and the need for inpatient or intensive parenteral glucose support.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two individuals initiated ersodetug prior to hospitalization, including one receiving continuous carbohydrate supplementation via home TPN.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Supportive strategies such as frequent carbohydrate intake or continuous parenteral dextrose infusion are often required but are burdensome and do not provide durable control, and parenteral infusions may prevent hospital discharge.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hospital stay after surgical resection versus endoscopic ultrasound-guided ablation of sporadic insulinoma
Postoperative length of stay after insulinoma resection (single center)
“A retrospective analysis of 33 patients who had an insulinoma resected and who underwent routine postoperative monitoring of blood glucose” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average postoperative length of hospital stay was 9 days” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Admission for glucose monitoring around hepatic artery embolization of insulinoma liver metastases
“The night before HAE, patients were admitted for blood glucose monitoring.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Liver-directed therapies control tumor burden and address severe associated hypoglycemia symptoms, the latter of which require vigilance and careful meal timing on an outpatient basis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Continuous intravenous support and cost of growth hormone therapy in non-islet cell tumor hypoglycemia (review)
“However, when prompt resection is not feasible, iv glucose or dextrose often does not suffice to prevent hypoglycemia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Continuous glucagon infusion can be successful if the patient has a positive response to a glucagon stimulation test, and parenteral nutrition may allow higher glucose delivery, but both are limited by the need for continuous iv infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recombinant human GH (rhGH) at supraphysiological doses of 3–12 mg daily has been successful in many cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, we propose that cost could be a limiting factor, especially for long-term therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost-of-illness or claims-based cost studies of insulinoma or NICTH
No evidence found.